IVIVA's preclinical kidney product integrates patient-derived cells and a novel biomimetic. Their proprietary scaffold construction technology uses 3D printing and membrane interposition to build thinly separated hollow vascular networks which are layered to create a composite matrix of relevant human scale. Patient-derived cells are used to create a product that may not require immunosuppression.
Lung Bioengineering is our innovative centralized ex vivo lung perfusion (EVLP) service. EVLP is designed to increase the pool of available donor lungs for transplantation and simplify the journey from organ offer to transplant.
Miromatrix develops bioengineered human organs using proprietary perfusion decellularization and recellularization technology that harnesses the powerful evolutionary forces shaping complex organ development and the regenerative capabilities of living human cells.
Thymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which - once inside the body - mature into cell types that can restore healthy T-cell function.
By restoring or modulating T-cell receptor diversity, Thymmune's technology could make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases.
Unither Bioelectronics is focused on designing and implementing an efficient and environmentally-friendly transportation system, including a fleet of autonomous aircraft, that is capable of delivering organs from organ manufacturing facilities to transplant centers within a single day, providing a logistical backbone for an unlimited supply of manufactured transplantable organs.
